Welcome to our dedicated page for CapsoVision SEC filings (Ticker: CV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc director King Wen-Herng Henry exercised restricted stock units to acquire 2,022 shares of Common Stock on June 30, 2026. The shares were acquired at a reported transaction price of $7.58 per share through the conversion of RSUs granted as equity compensation.
The RSUs were originally granted on March 19, 2026 using a fair market value of $6.18 per share and vest in two equal installments, on June 30 and December 31 of the applicable year. This transaction reflects vesting of one-half of the original RSU grant and the delivery of the underlying shares.
Following the transaction, Henry directly holds 25,619 shares of CapsoVision common stock and 2,023 RSUs, indicating remaining unvested equity from the same or other awards.
CapsoVision director Michele Harari reported the vesting of equity incentives that converted into common stock. On June 30, 2026, 2,022 Restricted Stock Units (RSUs) converted into 2,022 shares of CapsoVision common stock at a stated price of $0.00 per share.
These RSUs were part of an equity incentive grant made on March 19, 2026, using a fair market value of $6.18 per share. After the transaction, Harari directly holds 61,065 shares of common stock and 2,023 RSUs that remain outstanding and unvested.
CapsoVision, Inc director Julia S. Gouw exercised Restricted Stock Units to acquire additional common shares as part of her equity compensation. On 2026-06-30, she converted 2,022 RSUs into 2,022 shares of common stock, an exercise classified as a derivative conversion rather than an open-market purchase or sale.
The RSUs were originally granted on 2026-03-19 using a fair market value of $6.18 per share and vest in two equal installments on June 30 and December 31 of the applicable year. This transaction reflects the vesting of one half of the original grant and the delivery of the underlying shares. Following the transaction, Gouw directly holds 4,909 common shares and 2,023 RSUs, highlighting a compensation-driven increase in her equity stake rather than a discretionary market trade.
CapsoVision, Inc. reported the voting results from its 2026 annual meeting of stockholders held on June 11, 2026. Stockholders re-elected three Class I directors—Joanne Imperial, M.D., Wen-Herng (Henry) King, and Michele Harari—to serve until the 2029 annual meeting.
Support for each director was strong, with between 32,060,734 and 32,066,645 votes cast "for" and between 64,536 and 70,447 votes withheld, plus 2,244,596 broker non-votes for each nominee. Stockholders also ratified the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the 2026 fiscal year, with 34,321,524 votes for, 154 against, and 54,099 abstentions.
CapsoVision, Inc director and officer Wang Kang-Huai received a grant of stock options covering 358,344 shares of common stock at an exercise price of $6.90 per share. The options were granted at no cost and expire on June 1, 2036.
The grant vests as to 25% of the options on June 1, 2027, with the remaining 75% vesting in 36 equal monthly installments through June 1, 2030, subject to continued service. Following this award, Wang holds 629,304 derivative securities directly.
CapsoVision, Inc reported that Sr. VP of Finance David Michael Garcia received a grant of stock options covering 92,212 shares of common stock. The options have an exercise price of $6.90 per share and expire on June 1, 2036.
The grant is compensation-related, with no cash changing hands at the time of grant. Following this award, Garcia holds options for a total of 257,212 underlying shares. According to the vesting terms, 25% of the options vest on June 1, 2027, and the remaining 75% vest in 36 equal monthly installments through June 1, 2030, subject to continued service.
CapsoVision, Inc granted stock options to its Head of Global Sales, Douglas Patrick Atkinson. He received options to buy 158,078 shares of common stock at an exercise price of $6.90 per share, expiring on June 1, 2036.
The options vest as to 25% of the shares on June 1, 2027, with the remaining 75% vesting in 36 equal monthly installments through June 1, 2030, subject to continued service. Following this award, Atkinson holds a total of 176,847 stock options directly.
CapsoVision, Inc. reported first‑quarter 2026 results showing essentially flat revenue but higher losses as it invests in product development and clinical programs. Net revenue was $2,792 thousand, compared with $2,783 thousand a year earlier, while net loss widened to $7,033 thousand from $5,375 thousand.
Operating expenses rose to $8,422 thousand, driven mainly by research and development spending of $4,435 thousand as the company advances its CapsoCam Colon and AI initiatives. A March 2026 private placement added approximately $14,000 thousand in gross proceeds, lifting cash and cash equivalents to $17,933 thousand at March 31, 2026.
Despite the capital raise, management concluded that substantial doubt exists about CapsoVision’s ability to continue as a going concern within one year, given ongoing operating losses, negative operating cash flows of $6,066 thousand for the quarter, and the need for additional financing to meet growth and innovation objectives.
CapsoVision, Inc. reported first quarter 2026 revenue of $2.8 million, essentially unchanged from the prior year period, as a small decline in capsule volume was offset by a slightly higher average selling price. Gross margin fell to 48% from 54%, reflecting the impact of changes in U.S. trade policies and tariffs.
Operating expenses increased to $8.4 million, mainly from development work under a Canon Inc. agreement and clinical trials for the second-generation CapsoCam Colon, leading to a wider net loss of $7.0 million. Cash and cash equivalents rose to $17.9 million as of March 31, 2026, helped by completion of a $14 million private placement of equity on March 16, 2026. The company highlighted progress toward anticipated FDA clearance of its AI-assisted reading feature for CapsoCam Plus and ongoing pipeline programs in colon and pancreatic cancer diagnostics.
CapsoVision, Inc. ownership update: an amendment to a Schedule 13G/A reports that the Reporting Persons may be deemed to beneficially own an aggregate 5,100,867 shares of common stock as of March 26, 2026. The filing cites 49,838,211 shares outstanding as of March 25, 2026, producing reported percentages of 10.2% (Eliyahou Harari), 8.5% (Britt Harari), and 6.4% (Harari Family Trust). The schedule discloses direct ownership of 878,448 shares by Mr. Harari and indirect holdings through three trusts for which Mr. and Ms. Harari serve as trustees.